Personal Information
Entreprise/Lieu de travail
Greater New York City Area United States
Profession
Partner at Torreya Partners
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
http://www.torreyapartners.com
À propos
Tim Opler is a Partner at Torreya Partners where he provides advisory services to life sciences companies. Torreya Partners is a Leading Life Sciences M&A Boutique. His current clients include a wide variety of biotechnology companies, specialty pharmaceutical companies, medical device companies and diagnostics companies. He has advised on more than 100 transactions at Torreya including partnership deals, M&A transactions and financings. He has strong interest in the areas of allergy, fibrosis and nephrology. Most recently he was Vice-President, Strategy at FibroGen. At FibroGen, Tim was involved in a number of strategic, financial and operational matters. Previously, Tim was a Managing D...
Mots-clés
covid-19
business development
cancer
drugs
healthcare
gdp growth
china
peptides
implantables
future
pharma
pharmaceutical
Tout plus
Présentations
(3)Personal Information
Entreprise/Lieu de travail
Greater New York City Area United States
Profession
Partner at Torreya Partners
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
http://www.torreyapartners.com
À propos
Tim Opler is a Partner at Torreya Partners where he provides advisory services to life sciences companies. Torreya Partners is a Leading Life Sciences M&A Boutique. His current clients include a wide variety of biotechnology companies, specialty pharmaceutical companies, medical device companies and diagnostics companies. He has advised on more than 100 transactions at Torreya including partnership deals, M&A transactions and financings. He has strong interest in the areas of allergy, fibrosis and nephrology. Most recently he was Vice-President, Strategy at FibroGen. At FibroGen, Tim was involved in a number of strategic, financial and operational matters. Previously, Tim was a Managing D...
Mots-clés
covid-19
business development
cancer
drugs
healthcare
gdp growth
china
peptides
implantables
future
pharma
pharmaceutical
Tout plus